Scholarlink

<p>Diabetes imposes a substantial health burden, yet its macroeconomic consequences remain incompletely quantified. Here we use a health-augmented macroeconomic model to estimate output losses attributable to diabetes across 190 countries and territories during 2021–2050. We project that diabetes could reduce cumulative global output by 5.177 trillion international dollars over this period, with substantial heterogeneity in relative losses as a share of GDP across countries. Country-level burdens vary markedly, reflecting heterogeneity in demographic trends, macroeconomic conditions, diabetes prevalence, health-system capacity and treatment costs. Most projected output loss is attributable to diabetes-related disability rather than premature mortality. In this work, we provide comparable cross-country estimates of the long-run macroeconomic burden of diabetes, informing prioritization of prevention, treatment policies, and related investments.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The global economic burden of diabetes for 190 countries 2021-50: a macroeconomic modelling study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月5日

查看全文
  • Jinxi Li,
  • Ruxu Zhang,
  • Ruixi Li,
  • Qihua Song,
  • Yanhong Gong,
  • Chichen Zhang,
  • Xiaoxv Yin

摘要

Diabetes imposes a substantial health burden, yet its macroeconomic consequences remain incompletely quantified. Here we use a health-augmented macroeconomic model to estimate output losses attributable to diabetes across 190 countries and territories during 2021–2050. We project that diabetes could reduce cumulative global output by 5.177 trillion international dollars over this period, with substantial heterogeneity in relative losses as a share of GDP across countries. Country-level burdens vary markedly, reflecting heterogeneity in demographic trends, macroeconomic conditions, diabetes prevalence, health-system capacity and treatment costs. Most projected output loss is attributable to diabetes-related disability rather than premature mortality. In this work, we provide comparable cross-country estimates of the long-run macroeconomic burden of diabetes, informing prioritization of prevention, treatment policies, and related investments.